Thin
Long-acting acylated amylin analogue developed for dual-mechanism obesity management. Demonstrates exceptional synergistic efficacy when paired with GLP-1 receptor agonists.
Direct-from-manufacturer peptides engineered via solid-phase continuous synthesis, validated under stringent HPLC-MS characterization to ensure seamless import via Khorgos Gateway and compliance with Kazakh National Center (NCELS) criteria.
Long-acting acylated amylin analogue developed for dual-mechanism obesity management. Demonstrates exceptional synergistic efficacy when paired with GLP-1 receptor agonists.
16-amino-acid peptide encoded in mitochondrial DNA. Enhances AMPK phosphorylation, restores insulin sensitivity, and serves high-altitude metabolic resilience formulations.
Synthetic cyclic heptapeptide melanocortin agonist acting centrally to regulate neuro-endocrine pathways. Synthesized with precise disulfide bond closure and minimal isomer impurities.
Dual-agonist peptide targeting GLP-1 and glucagon receptors. Designed for breakthrough clinical pipelines in non-alcoholic steatohepatitis (MASH/NASH) and significant glycemic reduction.
The Republic of Kazakhstan is undergoing a historic structural transformation in its healthcare economics. Under the National Healthcare Development Concept and the state-backed Pharma 2029 Roadmap, the Ministry of Healthcare of Kazakhstan has set a clear mandate: increase domestic pharmaceutical production from under 20% to over 50% of domestic consumption. Central to this strategic push is the modernization of regional compounding factories in Almaty, Shymkent, and Karaganda.
Through the unified procurement framework operated by SK-Pharmacy (СК-Фармация), domestic tenders increasingly prioritize localized formulations of high-value therapeutics. However, while local secondary packaging and sterile fill-finish operations have achieved international standards, access to multi-kilogram and multi-ton quantities of high-purity, traceable active pharmaceutical ingredients (APIs)—particularly complex synthetic peptides—remains Kazakhstan's most significant supply chain vulnerability.
By establishing direct supply corridors with Thinheal's Industry 4.0 automated peptide synthesis facility in Hangzhou, Kazakh pharmaceutical enterprises and contract development labs eliminate speculative Western intermediary markups, achieve direct compliance with Eurasian Economic Union (EAEU) Pharmacopoeial monographs, and secure verified cold-chain routing across the Western Europe-Western China international transit highway.
Targeted active ingredients designed to address Central Asia's epidemiological imperatives, from chronic metabolic epidemics to neuro-regeneration and pastoral agricultural biosecurity.
Kazakhstan faces an escalating incidence of Type 2 Diabetes (T2D) and metabolic syndrome, impacting over 8% of the adult population. Our full suite of GLP-1, GLP-2, dual incretin agonists (Survodutide), and non-peptide oral mimics (Orforglipron) provides Kazakh manufacturers with scalable API raw materials for both long-acting injectable pens and oral solid dosage formulations.
Peptide therapeutics enjoy extensive clinical history across post-Soviet Central Asia. Biocompounds such as synthetic Thymalin, Semax, and Thymosin β4 Acetate (TB500) serve vital roles in immune reconstitution, ischemic stroke rehabilitation, and soft-tissue orthopedics across clinical centers in Astana and Almaty.
With Kazakhstan's vast steppe ecology and agricultural modernization programs, animal husbandry is a cornerstone of the national economy. Peptides such as Deslorelin provide precision veterinary reproductive control in equine breeding, cattle livestock management, and specialized camel husbandry without surgical risks.
Thinheal operates from Hangzhou Heda Medicine Valley, deploying automated solid-phase peptide synthesis (SPPS) and liquid-phase fragment condensation platforms. Unlike small laboratory suppliers, our industrial facility is engineered for multi-ton annual commercial throughput. Process safety, stereochemical purity, and complete deprotection kinetics are supervised via real-time Process Analytical Technology (PAT).
Our chemical synthesis pipelines leverage continuous solvent recycling and high-throughput axial compression DAC chromatography columns (up to 1,000 mm diameter). This engineering capability translates to major strategic advantages for international buyers: guaranteed lot-to-lot homogeneity, trace impurity suppression below ICH Q3A thresholds, and rapid production scale-up from pilot research grams to multi-kilogram commercial drug substance batches.
Geographically aligned with the Belt and Road Initiative, our logistics link seamlessly from Hangzhou to the Khorgos Gateway on the Sino-Kazakh border, enabling door-to-door delivery to Almaty or Astana within 5 to 7 days under continuous IoT temperature-logged refrigerated transport.
Navigating the transition toward green manufacturing, advanced lipidation platforms, and structural stabilization technologies.
By replacing manual batch cleavage with continuous-flow microwave-assisted solid-phase synthesis, we suppress epimerization at difficult couplings (such as sterically hindered Aib residues in GLP-1 sequences), slashing aggregation rates and boosting crude purity past 85% before chromatography.
Long-acting pharmacokinetic retention relies heavily on tailored fatty-acid side chains (e.g., mono-tert-butyl octadecanedioate). Thinheal provides pre-coupled, stereospecifically pure building blocks (Fmoc-Lys(Octadecanedioyl-OtBu)-OH), ensuring flawless site-specific conjugation for generic Tirzepatide and Semaglutide dossiers.
Recognizing global sustainability mandates, our facilities implement green peptide synthesis metrics: substituting toxic DMF and NMP with bio-derived cyclopentyl methyl ether (CPME) and 2-MeTHF, achieving a 45% reduction in Process Mass Intensity (PMI) and ensuring zero harmful residues in final lyophilized cakes.
Indicative commercial tiers for the Kazakhstan and EAEU markets. Final contract quotations vary depending on lot scale, target salt forms (Acetate vs. TFA-free), and required regulatory documentation packages.
| Active Ingredient Name | CAS Identifier | Therapeutic Class / Indication | Purity (HPLC) | Standard Pack Sizes | Regulatory Dossier Availability |
|---|---|---|---|---|---|
| Cargrilintide | 1415456-99-3 | Long-Acting Amylin Analogue / Obesity | ≥ 98.5% | 100g, 500g, 1kg, 5kg | CoA, HPLC, MS, Open-part DMF |
| Mots-C Peptide | 16 Amino Acids | Mitochondrial Derived / Metabolic Control | ≥ 99.0% | 10g, 50g, 250g, 1kg | CoA, MS, Amino Acid Analysis |
| Bremelanotide (PT-141) | 189691-06-3 | Melanocortin Receptor Agonist / CNS | ≥ 99.0% | 50g, 200g, 1kg, 5kg | CoA, HPLC, LC-MS, Impurity Profile |
| Survodutide | 2805997-46-8 | Dual GLP-1 / Glucagon Agonist (MASH) | ≥ 98.5% | 50g, 100g, 500g, 2kg | Synthesis Route, CoA, MS, Residual Solvents |
| Orforglipron | 2212020-52-3 | Oral Non-Peptide GLP-1 Receptor Agonist | ≥ 99.2% | 100g, 500g, 2kg, 10kg | Full Characterization, NMR, HPLC, Heavy Metals |
| Thymalin | 63958-90-7 | Thymic Polypeptide / Immune Recovery | ≥ 98.0% | 100g, 1kg, 5kg, 20kg | Synthetic Origin Cert, Bioburden, Endotoxin |
| Dulaglutide | 923950-08-7 | GLP-1 Fc Fusion Analogue / Diabetes T2D | ≥ 98.5% | 50g, 250g, 1kg, 5kg | CoA, Biological Potency, Stability Study |
| Copper Tripeptide (GHK-Cu) | 89030-95-5 | Matrix Remodeling / Dermal Aesthetic | ≥ 99.0% | 1kg, 5kg, 25kg drum | Cosmetic Dossier, Heavy Metals, REACH/EAEU |
| Semax Peptide | 80714-61-0 | Adrenocorticotropic Fragment / Nootropic | ≥ 99.0% | 50g, 200g, 1kg, 5kg | EAEU Pharmacopoeia Alignment, HPLC, MS |
| BPC-157 | 137525-51-0 | Gastric Pentadecapeptide / Tissue Repair | ≥ 99.0% | 100g, 500g, 2kg, 10kg | Acetate/TFA Salt Reports, Endotoxin Test |
| Thymosin β4 Acetate (TB500) | 77591-33-4 | Actin-Sequestering Peptide / Wound Care | ≥ 98.5% | 50g, 250g, 1kg, 5kg | Specific Optical Rotation, Peptide Content |
| Deslorelin | 57773-65-6 | GnRH Analog / Veterinary Reproduction | ≥ 99.0% | 25g, 100g, 500g, 2kg | Vet Formulation Support, Purity, Water Content |
Full commercial specifications for regulatory filling, compounding pharmacies, clinical R&D institutes, and livestock reproductive biotechnology operations.
Small-molecule oral non-peptide GLP-1 receptor agonist eliminating cold-chain constraints for rural clinics across Kazakhstan's expansive regional districts.
Pure chemical synthesis eliminating bovine viral contamination risks. Reconstitutes T-lymphocyte differentiation and immune parameters with strict batch reproducibility.
Long-acting once-weekly GLP-1 analogue engineered with IgG4-Fc fusion construct to slow renal clearance. High-yield commercial campaigns for generic drug filings.
Deep-blue crystalline copper tripeptide complex. Proven cellular signaling active accelerating fibroblast collagen type I/III synthesis for high-end aesthetic medicine.
ACTH(4-10) heptapeptide analogue stabilizing brain-derived neurotrophic factor (BDNF). Highly sought-after in post-stroke rehabilitation and cognitive recovery regimens.
Stable gastric pentadecapeptide known for rapid angiogenesis up-regulation and tendon-to-bone junction repair. Free of trifluoroacetic acid residuals upon client specification.
Synthetic actin-sequestering protein promoting keratinocyte and endothelial migration. Extensively utilized in dermal wound dressing formulations and cardiac remodeling studies.
Potent synthetic GnRH nonapeptide analogue. Primary active ingredient for reversible ovulation synchronization and fertility management in equine studs and agricultural herds.
Addressing regulatory harmonization, customs procedures at Khorgos, analytical releases, and temperature-controlled logistics across Central Asia.
Connect with Thinheal's dedicated Russian and CIS regional export desk. Request official batch CoAs, current 2025–2026 bulk pricelists, custom synthesis feasibility assessments, or EAEU-format registration files today.